Randomized phase III trial of erlotinib versus docetaxel in patients with advanced squamous cell non-small cell lung cancer failing first line platinum-based doublet chemotherapy stratified by Veristrat good versus Veristrat poor. The European Thorac
Authors : Peters S, Stahel RA, Dafni U, Aix SP, Massutí B, Gautschi O, Coate L, López Martín A, van Heemst R, Berghmans T, Meldgaard P, Cobo Dols M, Noguera JG, Curioni-Fontecedro A, Rauch D, Mark MT, Cuffe S, Biesma B, van Henten AM, Vidal ÓJ, Sanchez RP, Villa Guzmán JC, Martin RC, Peralta S, Insa A, Summers Y, Láng I, Horgan A, Ciardiello F, de Hosson S, Pieterman R, Groen HJ, van den Berg PM, Zielinski CC, Kuruvilla YC, Gasca-Ruchti A, Kassapian M, Novello S, Torri V, Tsourti Z, Gregorc V, Smit EF
Year : 2017
Journal : J Thorac Oncol
Volume : 12(4)
Pages : 752-62